Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Melanie White-Koning"'
Autor:
Anis Krache, Charlotte Fontan, Carine Pestourie, Manuel Bardiès, Yann Bouvet, Pierre Payoux, Etienne Chatelut, Melanie White-Koning, Anne-Sophie Salabert
Publikováno v:
Frontiers in Medicine, Vol 8 (2022)
Anti-PDL1 is a monoclonal antibody targeting the programmed death-cell ligand (PD-L1) by blocking the programmed death-cell (PD-1)/PD-L1 axis. It restores the immune system response in several tumours, such as non-small cell lung cancer (NSCLC). Anti
Externí odkaz:
https://doaj.org/article/7e88c75dd0124f899fc8b11d3c6144fe
Autor:
Etienne Chatelut, Fabienne Thomas, Félicien Le Louedec, Florent Puisset, Melanie White-Koning
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 10, Pp 1208-1220 (2021)
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 10, Pp 1208-1220 (2021)
Pharmacokinetic (PK) parameter estimation is a critical and complex step in the model‐informed precision dosing (MIPD) approach. The mapbayr package was developed to perform maximum a posteriori Bayesian estimation (MAP‐BE) in R from any populati
Autor:
Fabien Despas, Lucie Oberic, Melanie White-Koning, Loïc Ysebaert, Sandra De Barros, Etienne Chatelut, Fanny Gallais, Ben Allal
Publikováno v:
Clinical Pharmacology & Therapeutics. 110:220-228
Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL). Absolute lymphocyte count (ALC) is a clinical criterion used for the monitoring of CLL. Ibrutinib has several effects on lymphocytes, and has highly variable pharmacokine
Autor:
Laurence Venat-Bouvet, Melanie White-Koning, William Jacot, Alicja Puszkiel, Jacques Robert, Etienne Chatelut, Hortense Laharie-Mineur, Thomas Filleron, Valérie Le Morvan, N. Dohollou, Marc Debled, Florence Dalenc, Chantal Bernard-Marty, Alexandre Evrard, Caroline Delmas, Fabienne Thomas, Henri Roché, Jean-Christophe Boyer, Cécile Arellano, Christelle Vachoux
Publikováno v:
Clinical Pharmacology & Therapeutics. 109:1244-1255
Variations in clinical response to tamoxifen (TAM) may be related to polymorphic cytochromes P450 (CYPs) involved in forming its active metabolite endoxifen (ENDO). We developed a population pharmacokinetic (PopPK) model for tamoxifen and six metabol
Autor:
Laurence Gladieff, Etienne Chatelut, Marie Noëlle Paludetto, Florent Puisset, Félicien Le Louedec, Melanie White-Koning, Christine Chevreau
Publikováno v:
Cancer Chemotherapy and Pharmacology. 85:585-592
While doses of carboplatin are mostly individualized according to the Calvert equation based on estimated Glomerular Filtration Rate (eGFR), there is still uncertainty regarding the best formula to predict GFR. Since Janowitz et al. recently proposed
Autor:
Anis, Krache, Charlotte, Fontan, Carine, Pestourie, Manuel, Bardiès, Yann, Bouvet, Pierre, Payoux, Etienne, Chatelut, Melanie, White-Koning, Anne-Sophie, Salabert
Publikováno v:
Frontiers in medicine. 8
Anti-PDL1 is a monoclonal antibody targeting the programmed death-cell ligand (PD-L1) by blocking the programmed death-cell (PD-1)/PD-L1 axis. It restores the immune system response in several tumours, such as non-small cell lung cancer (NSCLC). Anti
Autor:
Etienne Chatelut, Joseph Berthier, Chloé Puiseux, Mathieu Alonso, Caroline Munzer, Melanie White-Koning, Marie Lambert, Laurence Malard, Marlène Pasquet, Arnaud Garnier, Gwennaelle Alphonsa
Publikováno v:
Pediatric Blood & Cancer. 68
Background Plasma cystatin C is a potential marker of the glomerular filtration rate (GFR), and urinary cystatin C has been proposed as a marker of tubular dysfunction. Procedure A prospective study (NCT02822404) was conducted to assess the benefit o
Autor:
Caroline Protin, Fanny Gallais, Ben Allal, Sandra De Barros, Fabienne Thomas, Anne Quillet-Mary, Melanie White-Koning, Etienne Chatelut, Lucie Oberic, Loïc Dupré, Fabien Despas, Loïc Ysebaert
Publikováno v:
Clinical Pharmacokinetics
Clinical Pharmacokinetics, 2020, 59 (9), pp.1171-1183. ⟨10.1007/s40262-020-00884-0⟩
Clinical Pharmacokinetics, Springer Verlag, 2020, 59 (9), pp.1171-1183. ⟨10.1007/s40262-020-00884-0⟩
Clinical Pharmacokinetics, 2020, 59 (9), pp.1171-1183. ⟨10.1007/s40262-020-00884-0⟩
Clinical Pharmacokinetics, Springer Verlag, 2020, 59 (9), pp.1171-1183. ⟨10.1007/s40262-020-00884-0⟩
Ibrutinib is used for the treatment of chronic lymphocytic leukemia and other lymphoid malignancies. The aim of this work is to develop a population pharmacokinetic model for ibrutinib and its dihydrodiol metabolite to quantify pharmacokinetic inter-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18466632280bd56f9f163b49b4fa5076
https://hal.science/hal-02989879/document
https://hal.science/hal-02989879/document
Autor:
V Le Morvan, Frédéric Pinguet, S Ellis, A Massoubre, Etienne Chatelut, Melanie White-Koning, Fabienne Thomas, Isabelle Solassol, Litaty Mbatchi, N Tafzi, R Despax, H. Roche, N Levasseur, Jacques Robert, Alexandre Evrard, P Marquet
Publikováno v:
Cancer Research. 78:P3-12
Supported by a PHRC grant (#09-18-005) Background: Recent literature has suggested that germline genetic variants of drug-metabolizing enzymes or CYP19A1 (coding for aromatase) may be involved in the systemic aromatase inhibitors (AI) concentrations
Autor:
Cécile Arellano, J-C Boyer, Fabienne Thomas, Jacques Robert, Alexandre Evrard, Melanie White-Koning, H. Roche, P Houyau, A Puzskiel, J Dauba, Christelle Vachoux, M Poublanc, Etienne Chatelut, V Le Morvan
Publikováno v:
Cancer Research. 78:P3-12
Supported by a PHRC grant (#09-18-005) Background: The role of CYP2D6 genetic polymorphisms and plasma levels of active metabolites of tamoxifen (TAM) on clinical response and occurrence of side effects remains controversial. We conducted a prospecti